Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability 3-09-2024, 19:00

Samsung Bioepis Releases 2024 Sustainability Report, Highlighting Progress in Accessibility and R&D Innovation 25-06-2024, 20:00

New York Film Academy Commences its Fourth Decade with a 16-02-2023, 00:09